• Western blot analysis of extracts of various cell lines, using AFF1 antibody (STJ29013) at 1:1000 dilution. Secondary antibody: HRP Goat Anti-rabbit IgG (H+L) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Enhanced Kit. Exposure time: 30s.
  • Immunofluorescence analysis of U2OS cells using AFF1 antibody (STJ29013).

Anti-AFF1 antibody (1124-1218) (STJ29013)

SKU:
STJ29013

Shipping:
Free Shipping
Current Stock:
Host: Rabbit
Applications: WB/IF
Reactivity: Human/Rat
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit polyclonal antibody anti-AFF1 (1124-1218) is suitable for use in Western Blot and Immunofluorescence research applications.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Formulation: PBS with 0.02% Sodium Azide, 50% Glycerol, pH7.3.
Purification: Affinity purification
Dilution Range: WB 1:500-1:2000
IF/ICC 1:50-1:100
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: AFF1
Gene ID: 4299
Uniprot ID: AFF1_HUMAN
Immunogen Region: 1124-1218
Immunogen: Recombinant fusion protein containing a sequence corresponding to amino acids 1124-1218 of human AFF1 (NP_001160165.1).
Immunogen Sequence: SQSSAGSVGSSGVAATISTP VTIQNMTSSYVTITSHVLTA FDLWEQAEALTRKNKEFFAR LSTNVCTLALNSSLVDLVHY TRQGFQQLQELTKTP
Protein Name Af4/Fmr2 Family Member 1
All1-Fused Gene From Chromosome 4 Protein
Protein Af-4
Protein Fel
Proto-Oncogene Af4
Cellular Localisation Nucleus
Alternative Antibody Names Anti-Af4/Fmr2 Family Member 1 antibody
Anti-All1-Fused Gene From Chromosome 4 Protein antibody
Anti-Protein Af-4 antibody
Anti-Protein Fel antibody
Anti-Proto-Oncogene Af4 antibody
Anti-AFF1 antibody
Anti-AF4 antibody
Anti-FEL antibody
Anti-MLLT2 antibody
Anti-PBM1 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance